



## Pixium Vision announces resumption of Prima System feasibility study in France

- *Patient rehabilitation and recruiting had been postponed due to COVID-19 situation*
- *Pixium Vision continues preparations for PRIMAvera pivotal study*

**Paris, 8 June 2020** – 17.45 CET– Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, today announces the resumption of the feasibility study of its Prima System in France, as the strain of COVID-19 on healthcare systems eases.

Pixium Vision had decided in March 2020 to place its rehabilitation program of the feasibility study in France on hold to reduce demand on healthcare workers and institutions and avoid putting patients at risk. Patients in the French study, who have already been implanted with the PRIMA implant, have now resumed the rehabilitation process, a process taking several months during which implanted patients are taught how to best use the Prima System in order to optimize their visual experience. 36-month data are expected at the end of 2020.

“We are excited to continue the follow-up process and regain the momentum our patients experienced over the last two years of the study. The results to date are extremely encouraging and we look forward to entering the next phase where we will better understand the potential utility in tasks of daily living and subsequent improvements in quality of life,” stated Dr. Saddek Mohand-Saïd, Chief of the Clinical Trials Center, Hospital Quinze-Vingts (Paris, France).

In the US, a second feasibility study had started, having implanted and activated 2 patients. Given the COVID-19 situation the rehabilitation program for these patients as well as the recruitment of further patients was also placed on hold and is expected to resume as soon as the situation allows.

Recently reported 18-month data have shown the ability of patients to combine natural residual vision with prosthetic central vision in the dry age-related macular degeneration (AMD) population. Patients had a significant improvement in vision, gaining on average a logMAR of 0.5 (corresponding to 5 lines improvement) which may make the difference between recognizing letters on a street sign or not. The project can move forward to a pivotal study which will confirm the safety and the benefits provided to the patients and allow for market approval.

*“We are very pleased to have been able to quickly resume our feasibility study in France and move forward with this exciting project. The Prima System has shown excellent results in improving patients’ vision and it clearly has the potential to significantly improve the quality of life and restore a level of independence for people suffering from dry AMD and who currently have no treatment options. » We are looking forward to generating further data from this French study and to move forward with the filing of our PRIMAvera pivotal study as soon as the COVID-19 situation allows,”* said **Lloyd Diamond, Chief Executive Officer of Pixium Vision.**

## Contacts

### Pixium Vision

Lloyd Diamond  
Chief Executive Officer  
[investors@pixium-vision.com](mailto:investors@pixium-vision.com)  
+33 1 76 21 47 49

### Media relations LifeSci Advisors

Sophie Baumont  
[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)  
+33 6 27 74 74 49

### Investor relation LifeSci Advisors

Guillaume van Renterghem  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)  
+33 6 69 99 37 83

**Pixium Vision** is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information: <http://www.pixium-vision.com/fr>

Follow us on [@PixiumVision](https://twitter.com/PixiumVision); [www.facebook.com/pixiumvision](https://www.facebook.com/pixiumvision)

[Linkedin www.linkedin.com/company/pixium-vision](https://www.linkedin.com/company/pixium-vision)



Pixium Vision is listed on Euronext Growth Paris.  
Euronext ticker: ALPIX - ISIN: FR0011950641

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext GROWTH ALLSHARE index